HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Everest Medicines (1952.HK) - The Commercialization Prospect Has Reshaped

Changchun High & New Tech (000661.CH) - Insights on Recent Pullback & The Future Business Outlook

Pre-IPO Brii Biosciences - Insights on Pipeline and Related Concerns

Shanghai Junshi Bioscience - Here Are the Challenges

I-Mab Placement - Heading in the Right Direction

Genor Biopharma (6998.HK) - Here Is Why the Stock Price Decreased by About 50%

Gravity Works As WeWork Doesn't; Now Plan B

Bifurcated Chinese Express Market Developing

Equity Bottom-Up

<p>As a well-known clinical-stage biopharmaceutical company in China, <a href="https://www.smartkarma.com/entities/i-mab" target="_blank" data-smartkarma-citation="entities:28384:1" rel="noopener">I-Mab (IMAB US)</a> has been developing rapidly in recent years. Meanwhile, its share price skyrocketed from the issue price of $14/share in the beginning of 2020 to $46.62/share on March 26, 2021, up about 233% in more than a year and with the market value of $3.35 billion. The reason why I-MAB is worth investors' attention in 2021 is that the Company has come to a key phase from R&amp;D to commercialization. The following mainly included insights on its core products TJC4, TJ202 and TJ101.</p>

As a well-known clinical-stage biopharmaceutical company in China, I-Mab (IMAB US) has been developing rapidly in recent years. Meanwhile, its share price skyrocketed from the issue price of $14/share in the beginning of 2020 to $46.62/share on March 26, 2021, up about 233% in more than a year and with the market value of $3.35 billion. The reason why I-MAB is worth investors' attention in 2021 is that the Company has come to a key phase from R&amp;D to commercialization. The following mainly included insights on its core products TJC4, TJ202 and TJ101.

Anhui Anke Biotechnology (Group) (300009 CH)

Xiamen Amoytop Biotech Co Ltd (688278 CH)

I-Mab (IMAB US) - Insights On Core Products TJC4, TJ202 and TJ101